Navigation Links
Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Date:1/30/2008

SCHAUMBURG, Ill., Jan. 30 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company with a focus on injectable products, today announced that Ronald E. Pauli, chief financial officer, will present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on Tuesday, February 5, 2008, at 11 a.m. EST. The conference will be held February 5-7, 2008 at the Grand Hyatt Hotel in New York.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific focus on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

For more information about Sagent, please visit http://www.sagentpharma.com.


'/>"/>
SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
2. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
3. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
4. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
5. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
6. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
7. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
8. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
9. Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors
10. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... The Osteoarthritis Research ... Federal Drug Administration (FDA) to consider OA as a serious disease. As an ... the growing population of OA patients, many of whom may experience progressive disability ...
(Date:12/6/2016)... , ... December 06, 2016 , ... ... plasma technology platforms, announced today that the company has engaged in a collaborative ... Development Agreement (MRDA) with the CSU Office of the Vice President for Research. ...
(Date:12/6/2016)... SAN DIEGO , Dec. 6, 2016 ... of Santosh Kesari , MD, PhD, FANA, FAAN ... his experience in neurology and clinical trials to assist ... for treatment of stroke. The AmnioStem product is a universal ... previously shown therapeutic activity in animal models of stroke ...
(Date:12/6/2016)... 6, 2016  The Texas Medical Center ... (HISA) today announced the establishment of a new ... Australia and the Texas Medical ... HISA and the Texas Medical Center, with ... create a global health innovation ecosystem where emerging technologies ...
Breaking Biology Technology:
(Date:11/21/2016)... Nov. 21, 2016   Neurotechnology , a ... technologies, today announced that the MegaMatcher On Card ... submitted for the NIST Minutiae Interoperability Exchange ... the mandatory steps of the evaluation protocol. ... continuing test of fingerprint templates used to establish ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
(Date:6/22/2016)... -- The American College of Medical Genetics and Genomics was once ... one of the fastest-growing trade shows during the Fastest 50 ... Las Vegas . Winners ... each of the following categories: net square feet of paid ... The 2015 ACMG Annual Meeting was ranked 23 out of ...
Breaking Biology News(10 mins):